MarketCap
Facebook
X
Telegram
Cardinal Health Income Statement 2025-2011 | CAH
Brief overview of profit and loss at Cardinal Health
The overview follows changes across a five-year period. Revenue reported by Cardinal Health was $153 billion at the beginning of the period and $223 billion at the end. The five-year change reached +45.6%, while CAGR stood at 7.8%. Revenue advanced gradually over the five-year period.
The five-year change in gross profit reached +18.9%: from 6.9 billion dollars to 8.2 billion dollars. There was no major divergence between sales and cost of revenue. Gross margin moved from 4.5% to 3.7%. The relationship between gross profit and revenue changed only slightly.
The five-year EBITDA result moved by +196.2%: from −$3.2 billion to $3.1 billion. EBITDA expanded faster than the top line. EBITDA margin moved from −2.1% to 1.4%. The company improved its ability to convert sales into EBITDA.
The final result was −$3.7 billion initially and $1.6 billion in the final year. A negative result turned positive over the five years.
The market value of the business moved from 14.9 billion dollars to 35.3 billion dollars, or +136%. Investors assigned a higher value to the business over time.
Conclusion
The financial profile remains mixed, with strengths and risks moving in different directions. The constructive conclusion rests on consistent sales economics, a stronger final result and revenue expansion. The weaker side of the profile includes a low EBITDA margin and a narrow gross-profit buffer. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Cardinal Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
35.3 B | 26.1 B | 23.6 B | 16.5 B | 14.9 B | 14.9 B | 13.9 B | 15.7 B | 24.6 B | 27.3 B | 27.7 B | 24.8 B | 17.1 B | 14.9 B | 15.3 B |
Shares |
241 M | 245 M | 261 M | 279 M | 292 M | 293 M | 300 M | 313 M | 317 M | 327 M | 332 M | 341 M | 341 M | 345 M | 349 M |
Historical Prices |
146 | 106 | 90.6 | 59.3 | 51.1 | 51.4 | 47.1 | 44.1 | 60.8 | 61.6 | 65.5 | 65.8 | 52.8 | 33.2 | 31.8 |
Net Income |
1.56 B | 852 M | 330 M | -77 M | 611 M | -3.7 B | 1.36 B | 256 M | 1.29 B | 1.43 B | 1.22 B | 1.17 B | 334 M | 1.07 B | 959 M |
Revenue |
223 B | 227 B | 205 B | 51.5 B | 162 B | 153 B | 146 B | 137 B | 130 B | 122 B | 103 B | 91.1 B | 101 B | 108 B | 103 B |
Cost of Revenue |
214 B | 219 B | 198 B | 49.8 B | 156 B | 146 B | 139 B | 130 B | 123 B | 115 B | - | - | - | - | - |
Gross Profit |
8.17 B | 7.41 B | 6.87 B | 1.68 B | 6.78 B | 6.87 B | 6.83 B | 7.18 B | 6.54 B | 6.54 B | 5.71 B | 5.16 B | 4.92 B | 4.54 B | 4.16 B |
Operating Income |
2.28 B | 1.24 B | 752 M | -86 M | 472 M | -4.1 B | 2.06 B | 126 M | 2.12 B | 2.46 B | 2.16 B | 1.88 B | 996 M | 1.79 B | 1.51 B |
Interest Expense |
215 M | 51 M | 84 M | 24 M | 180 M | 238 M | 294 M | 329 M | 201 M | 178 M | 141 M | 133 M | 123 M | 95 M | 93 M |
EBITDA |
3.06 B | 1.95 B | 1.44 B | 606 M | 1.26 B | -3.18 B | 2.35 B | 2.58 B | 2.77 B | 2.9 B | 2.47 B | 2.13 B | 2.05 B | 1.86 B | 1.88 B |
Operating Expenses |
- | - | - | - | - | - | 5.1 B | 5.3 B | 4.3 B | 4.11 B | 3.52 B | 3.25 B | 3.03 B | 2.71 B | 2.59 B |
General and Administrative Expenses |
5.38 B | 5 B | 4.8 B | 1.18 B | 4.53 B | 4.57 B | 4.48 B | 4.6 B | 3.78 B | 3.65 B | 3.24 B | 3.03 B | 2.88 B | 2.68 B | 2.59 B |
All numbers in USD currency
Quarterly Income Statement Cardinal Health
| 2025-Q4 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
236 M | 240 M | 242 M | 243 M | 243 M | 245 M | 249 M | 256 M | 261 M | 271 M | 266 M | 275 M | 279 M | 287 M | 283 M | 292 M | 294 M | 293 M | 294 M | 293 M | 292 M | 296 M | 292 M | 296 M | 299 M | 305 M | 299 M | 305 M | 315 M | 316 M | 315 M | 316 M | 318 M | 320 M | 318 M | 320 M | 329 M | 328 M | 329 M | 328 M | 331 M | 336 M | 331 M | 336 M | 342 M | 340 M | 342 M | 340 M | 340 M | 341 M | 340 M | 341 M | 345 M | 345 M | 345 M | 345 M |
Net Income |
467 M | 506 M | 400 M | 416 M | 261 M | 368 M | -12 M | 345 M | -130 M | 110 M | -20 M | -1.39 B | 49 M | 271 M | 320 M | 119 M | 629 M | -253 M | 629 M | -253 M | 220 M | -4.92 B | 220 M | -4.92 B | 280 M | 593 M | 280 M | 593 M | 1.05 B | 115 M | 1.05 B | 115 M | 324 M | 309 M | 324 M | 309 M | 326 M | 383 M | 326 M | 383 M | 289 M | 266 M | 289 M | 266 M | 278 M | 339 M | 278 M | 339 M | 303 M | 271 M | 303 M | 271 M | 262 M | 237 M | 262 M | 237 M |
Revenue |
65.6 B | 54.9 B | 55.3 B | 52.3 B | 54.9 B | 57.4 B | 54.6 B | 50.5 B | 51.5 B | 49.6 B | 101 B | 44.8 B | 45.5 B | 44 B | 89.4 B | 39.3 B | 41.5 B | 39.1 B | 41.5 B | 39.1 B | 39.7 B | 37.3 B | 39.7 B | 37.3 B | 37.7 B | 35.2 B | 37.7 B | 35.2 B | 35.2 B | 32.6 B | 35.2 B | 32.6 B | 33.2 B | 32 B | 33.2 B | 32 B | 31.4 B | 28.1 B | 31.4 B | 28.1 B | 25.5 B | 24.1 B | 25.5 B | 24.1 B | 22.2 B | 24.5 B | 22.2 B | 24.5 B | 25.2 B | 25.9 B | 25.2 B | 25.9 B | 27.1 B | 26.8 B | 27.1 B | 26.8 B |
Cost of Revenue |
63.2 B | 52.8 B | 53.3 B | 50.4 B | 52.9 B | 55.6 B | 52.9 B | 48.7 B | 49.8 B | 48 B | 97.8 B | 43.2 B | 43.8 B | 42.3 B | 86.2 B | 37.5 B | 39.8 B | 37.4 B | 39.8 B | 37.4 B | 38 B | 35.7 B | 38 B | 35.7 B | 36 B | 33.5 B | 36 B | 33.5 B | 33.3 B | 31 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
2.4 B | 2.12 B | 1.94 B | 1.9 B | 1.94 B | 1.85 B | 1.74 B | 1.78 B | 1.66 B | 1.61 B | 3.28 B | 1.68 B | 1.62 B | 1.64 B | 3.26 B | 1.81 B | 1.78 B | 1.72 B | 1.78 B | 1.72 B | 1.71 B | 1.68 B | 1.71 B | 1.68 B | 1.73 B | 1.67 B | 1.73 B | 1.67 B | 1.86 B | 1.67 B | 1.86 B | 1.67 B | 1.6 B | 1.59 B | 1.6 B | 1.59 B | 1.61 B | 1.58 B | 1.61 B | 1.58 B | 1.45 B | 1.34 B | 1.45 B | 1.34 B | 1.34 B | 1.26 B | 1.34 B | 1.26 B | 1.22 B | 1.16 B | 1.22 B | 1.16 B | 1.11 B | 1.08 B | 1.11 B | 1.08 B |
Operating Income |
707 M | 730 M | 549 M | 568 M | 369 M | 505 M | -32 M | 572 M | -119 M | 137 M | 18 M | -97 M | -950 M | 415 M | -535 M | 473 M | 461 M | -624 M | 461 M | -624 M | 334 M | -5.26 B | 334 M | -5.26 B | 504 M | 816 M | 504 M | 816 M | 399 M | 262 M | 399 M | 262 M | 542 M | 535 M | 542 M | 535 M | 563 M | 620 M | 563 M | 620 M | 546 M | 466 M | 546 M | 466 M | 519 M | 471 M | 519 M | 471 M | 506 M | 457 M | 506 M | 457 M | 449 M | 412 M | 449 M | 412 M |
Interest Expense |
88 M | 74 M | 35 M | 32 M | 28 M | 3 M | 11 M | 28 M | 25 M | 25 M | 50 M | 38 M | 37 M | 40 M | 77 M | 45 M | 46 M | 45 M | 46 M | 45 M | 63 M | 66 M | 63 M | 66 M | 76 M | 77 M | 76 M | 77 M | 87 M | 81 M | 87 M | 81 M | 44 M | 44 M | 44 M | 44 M | 45 M | 44 M | 45 M | 44 M | 36 M | 34 M | 36 M | 34 M | 33 M | 33 M | 33 M | 33 M | 27 M | 26 M | 27 M | 26 M | 23 M | 23 M | 22.9 M | 23.5 M |
EBITDA |
941 M | 807 M | 741 M | 750 M | 433 M | 568 M | 140 M | 641 M | -48 M | 308 M | 359 M | -19 M | -871 M | 583 M | -203 M | 582 M | 574 M | -419 M | 865 M | -419 M | 461 M | -5.03 B | 798 M | -5.03 B | 637 M | 1.06 B | 1 B | 1.06 B | 551 M | 491 M | 919 M | 491 M | 637 M | 708 M | 881 M | 708 M | 664 M | 757 M | 869 M | 757 M | 593 M | 574 M | 766 M | 574 M | 565 M | 588 M | 753 M | 588 M | 529 M | 545 M | 682 M | 478 M | 468 M | 490 M | 605 M | 490 M |
General and Administrative Expenses |
1.5 B | 1.32 B | 1.31 B | 1.28 B | 1.27 B | 1.27 B | 1.19 B | 1.18 B | 1.19 B | 1.2 B | 2.39 B | 1.14 B | 1.15 B | 1.11 B | 2.26 B | 1.12 B | 1.15 B | 1.14 B | 1.15 B | 1.14 B | 1.16 B | 1.11 B | 1.16 B | 1.11 B | 1.06 B | 1.16 B | 1.06 B | 1.16 B | 1.13 B | 1.06 B | 1.13 B | 1.06 B | 910 M | 920 M | 910 M | 920 M | 922 M | 842 M | 922 M | 842 M | 815 M | 775 M | 815 M | 775 M | 766 M | 732 M | 766 M | 732 M | 699 M | 690 M | 699 M | 690 M | 640 M | 644 M | 640 M | 643 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Cardinal Health (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical distribution industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
AmerisourceBergen Corporation
ABC
|
- | -0.23 % | $ 37.5 B |  USA |
 |
PPD, Inc.
PPD
|
- | 0.13 % | $ 16.6 B | USA |
 |
Owens & Minor
OMI
|
- | - | $ 215 M | USA |
 |
Patterson Companies
PDCO
|
- | -0.87 % | $ 3 B | USA |
 |
Henry Schein
HSIC
|
$ 85.75 | 0.68 % | $ 10.4 B | USA |
 |
Prestige Consumer Healthcare
PBH
|
$ 50.22 | 0.54 % | $ 2.43 B | USA |
 |
McKesson Corporation
MCK
|
$ 856.19 | -1.08 % | $ 138 B | USA |